<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029336</url>
  </required_header>
  <id_info>
    <org_study_id>19-016604</org_study_id>
    <nct_id>NCT05029336</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases</brief_title>
  <official_title>Autologous Hematopoietic Stem Cell Transplant for Children and Young Adults With Life Threatening Autoimmune Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stephan Grupp MD PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and&#xD;
      unresponsive to conventional treatments. In these patients, the delivery of high dose&#xD;
      immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a&#xD;
      treatment strategy capable of purging the pathogenic, autoreactive immune system and an&#xD;
      opportunity for &quot;immune reset.&quot; This strategy has been used in adults across a myriad of&#xD;
      indications with evidence for efficacy. This study proposes a pilot study to evaluate this&#xD;
      therapeutic strategy in children and young adults with systemic sclerosis (SSc) and systemic&#xD;
      lupus erythematosis (SLE), two potentially life threatening autoimmune diseases that may&#xD;
      response to this therapeutic approach.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">May 2031</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open label single arm pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two-year progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Survival without evidence of relapse or disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-specific response/progression endpoints: SSc cohort</measure>
    <time_frame>24 months following transplant</time_frame>
    <description>o Pulmonary function: Change in forced vital capacity (FVC), total lung capacity (TLC) or diffusing capacity of the lung for carbon monoxide (DLCO) &gt; 10%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific response/progression endpoints: SSc cohort</measure>
    <time_frame>24 months following transplant</time_frame>
    <description>o Skin condition: An improvement is indicated by a decrease on modified Rodan Skin Score (mRSS) of &gt; 5 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific response/progression endpoints: Systemic Lupus Erythematosus (SLE) cohort</measure>
    <time_frame>24 months following transplant</time_frame>
    <description>o Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) &lt; 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific response/progression endpoints: Systemic Lupus Erythematosus (SLE) cohort</measure>
    <time_frame>24 months following transplant</time_frame>
    <description>o Complete remission off therapy (BILAG D/E only or SLEDAI=0 and no SLE treatment except hydroxychloroquine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific response/progression endpoints: Systemic Lupus Erythematosus (SLE) cohort</measure>
    <time_frame>24 months following transplant</time_frame>
    <description>o Serologic response: presence of positive ANA, anti-dsDNA and anticardiolpin antibody titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific response/progression endpoints: Systemic Lupus Erythematosus (SLE) cohort</measure>
    <time_frame>24 months following transplant</time_frame>
    <description>o Serologic response: abnormal complement C3 and C4 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 and 5 years following transplant</time_frame>
    <description>Overall survival will be considered as time from transplant to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>2 and 5 years following transplant</time_frame>
    <description>Events include death, and significant persistent organ damage&#xD;
o An event based on organ dysfunction must be documented on at least two occasions, at least three months apart and include: respiratory failure (resting O2 saturation &lt; 88%), renal failure (chronic dialysis) and cardiomyopathy (clinical congestive heart failure New York Class III or IV, left ventricular ejection fraction (LVEF) &lt; 30% by echocardiogram despite therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100 day treatment-related mortality</measure>
    <time_frame>100 days from stem cell infusion</time_frame>
    <description>Defined as death from non-disease related causes in the 100 days from stem cell infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to engraftment</measure>
    <time_frame>3 days</time_frame>
    <description>• Achieving an absolute neutrophil count (ANC) &gt; 500 cells/uL and an unsupported platelet count of &gt; 20,000 cells/uL for three consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>prior to autologous stem cell transplant (ASCT) until 5 years post-transplant</time_frame>
    <description>Quality of life will be measured based on the Patient-Reported Outcomes measurement Information System (PROMIS) that evaluates physical, mental and social health in adults and children.&#xD;
patient reported outcome measurement information system (PROMIS) will be administered to each patient (or proxy) prior to autologous stem cell transplant (ASCT) and three times/year for the first two years post-transplant and then annually until five years post-transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>CD3/CD19 depleted ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The test article is autologous stem cell transplant with a CD3/CD19-depleted stem cell product.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Depletion of CD3/CD19 in an autologous stem cell transplant</intervention_name>
    <description>The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.</description>
    <arm_group_label>CD3/CD19 depleted ASCT</arm_group_label>
    <other_name>CD3/CD19 depletion using cliniMACs device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 8 ≤ 25 years at time of enrollment.&#xD;
&#xD;
          2. Severe systemic sclerosis or systemic lupus erythematosus based on specific criteria&#xD;
&#xD;
          3. Adequate organ function status&#xD;
&#xD;
          4. No active, untreated infections.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous hematopoietic stem cell transplant (HSCT) or solid organ transplant&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Ongoing participation in a clinical trial testing an investigational drug or ongoing&#xD;
             receipt of disallowed disease modifying anti-rheumatic drugs (DMARD)&#xD;
&#xD;
          4. Severe comorbidity that jeopardizes the ability of the subject to tolerate therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caitlin Elgarten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica H Lee, BS</last_name>
    <phone>267-425-1935</phone>
    <email>leej11@chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caitlin Elgarten, MD</last_name>
    <phone>2158079038</phone>
    <email>elgartenc@chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>267-425-1935</phone>
      <email>leej11@chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Principal investigator</last_name>
      <phone>2158079038</phone>
      <email>elgartenc@chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Caitlin Elgarten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Stephan Grupp MD PhD</investigator_full_name>
    <investigator_title>Director of Cancer Immunotherapy Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

